Ocugen ( OCGN -6.48%) Q3 2024 Earnings Call Nov 08, 2024, 8:30 a.m. ET Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator instructions] I will now ...

Additionally, promising data from the ALLO-316 Phase 1 trial in renal cell carcinoma has led to a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Financially, Allogene ended ...

UC San Francisco treated its first brain cancer patient with an experimental new CAR-T therapy discovered and manufactured at ...

Researchers from the Center for Regenerative Medicine (CReM) and the Department of Medicine at Boston Medical Center (BMC) ...

By studying changes in gene expression, researchers learn how cells function at a molecular level, which could help them ...

Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is paving for them, according to a panel of executives who spoke at the BioFuture ...

Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an ...

The stocks for both Swiss and Israeli biotechs were up over 20% after the companies signed a merger agreement.

Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell ...

Collaboration Revenue: Collaboration revenue generated through the company's collaboration, option, and license agreement with Bristol-Myers Squibb was $0.8 million for the three months ended ...

Beam Therapeutics (BEAM) stock falls as patient dies after receiving the company's gene editing therapy.in an early-stage ...

Cellectis is confident about the continued progress of its ongoing clinical trials in hematological malignancies and is ...